DE602004031225D1 - 3-oxa-8-azaprostaglandinanaloga als mittel zum senken des augeninnendrucks - Google Patents

3-oxa-8-azaprostaglandinanaloga als mittel zum senken des augeninnendrucks

Info

Publication number
DE602004031225D1
DE602004031225D1 DE602004031225T DE602004031225T DE602004031225D1 DE 602004031225 D1 DE602004031225 D1 DE 602004031225D1 DE 602004031225 T DE602004031225 T DE 602004031225T DE 602004031225 T DE602004031225 T DE 602004031225T DE 602004031225 D1 DE602004031225 D1 DE 602004031225D1
Authority
DE
Germany
Prior art keywords
azaprostaglandinanaloga
reminder
oxa
lowering eye
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004031225T
Other languages
English (en)
Inventor
David W Old
Thang D Dinh
Robert M Burk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE602004031225D1 publication Critical patent/DE602004031225D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602004031225T 2003-06-02 2004-05-25 3-oxa-8-azaprostaglandinanaloga als mittel zum senken des augeninnendrucks Expired - Lifetime DE602004031225D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/453,207 US6734206B1 (en) 2003-06-02 2003-06-02 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
PCT/US2004/016516 WO2004108670A1 (en) 2003-06-02 2004-05-25 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure

Publications (1)

Publication Number Publication Date
DE602004031225D1 true DE602004031225D1 (de) 2011-03-10

Family

ID=32230466

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004031225T Expired - Lifetime DE602004031225D1 (de) 2003-06-02 2004-05-25 3-oxa-8-azaprostaglandinanaloga als mittel zum senken des augeninnendrucks

Country Status (10)

Country Link
US (1) US6734206B1 (de)
EP (1) EP1638936B1 (de)
JP (1) JP2006526638A (de)
AT (1) ATE496886T1 (de)
AU (1) AU2004245492B2 (de)
BR (1) BRPI0410926A (de)
CA (1) CA2528010C (de)
DE (1) DE602004031225D1 (de)
ES (1) ES2358513T3 (de)
WO (1) WO2004108670A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734201B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
DK1960353T3 (da) 2005-11-03 2014-05-26 Allergan Inc Prostaglandiner og analoger som midler til sænkning af intraokulært tryk
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8783923B2 (en) * 2010-03-18 2014-07-22 Chung Yuan Christian University Auto lamp structure

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US6545045B1 (en) * 1998-12-24 2003-04-08 Alcon Manufacturing, Ltd. Prostaglandin E agonists for treatment of glaucoma
AP2002002555A0 (en) 1999-12-22 2002-06-30 Pfizer Prod Inc EP4 Receptor selective agonists in the treatment of osteoporosis.
IL141120A0 (en) 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
JP4063468B2 (ja) 2000-02-22 2008-03-19 株式会社カネボウ化粧品 寒天被覆処理顔料およびメイクアップ化粧料
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
CN1476429A (zh) * 2000-11-27 2004-02-18 �Ʒ� 治疗骨质疏松的ep4受体选择性激动剂
WO2002102389A1 (en) 2001-06-14 2002-12-27 Allergan, Inc. 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
EP1409455B1 (de) * 2001-07-16 2006-01-04 F. Hoffmann-La Roche Ag Prostaglandinanaloga als ep4-rezeptoragonisten
BR0211167A (pt) 2001-07-16 2004-08-10 Hoffmann La Roche Derivados de 2-pirrolidona como agonistas de prostanóides
WO2003009872A1 (en) 2001-07-23 2003-02-06 Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
MXPA04009036A (es) * 2002-03-18 2005-01-25 Pfizer Prod Inc Uso de agonistas del receptor ep4 selectivos para el tratamiento de la insuficiencia hepatica, perdida de permeabilidad del ductus arterioso, glaucoma o hipertension ocular.
DE60307607T2 (de) * 2002-03-18 2007-08-09 Pfizer Products Inc., Groton Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten

Also Published As

Publication number Publication date
EP1638936B1 (de) 2011-01-26
CA2528010C (en) 2012-01-24
BRPI0410926A (pt) 2006-06-27
CA2528010A1 (en) 2004-12-16
US6734206B1 (en) 2004-05-11
ATE496886T1 (de) 2011-02-15
JP2006526638A (ja) 2006-11-24
EP1638936A1 (de) 2006-03-29
AU2004245492A1 (en) 2004-12-16
WO2004108670A1 (en) 2004-12-16
AU2004245492B2 (en) 2010-08-19
ES2358513T3 (es) 2011-05-11

Similar Documents

Publication Publication Date Title
DE50312946D1 (de) Difluormethyl thiazolyl carboxanilide
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
TW200700070A (en) Enhanced bimatoprost ophthalmic solution
NO20070606L (no) Inhibitorer av IAP
BR0310047A (pt) Análogos de 8-azaprostaglandina como agentes para diminuição de pressão intra-ocular
DE50306845D1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
TW200630374A (en) Thiazolyldihydroindazoles
DE60026155D1 (de) Einige alkylendiamin-substituierte heterocyclen
NO20064282L (no) Morfolinforbindelser
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
TW200500339A (en) Pyrrolidine derivatives, and process for the preparation
CY1108808T1 (el) Ενωσεις μοτιλιδης
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
EP1627635A3 (de) Benzothiazolium Verbindungen zur Verwendung in Methoden zur Hemmung der NO Produktion und von TNF alpha und zur Behandlung von Coronavirus Infektionen
DE602005017815D1 (de) Behandlung von entzündlicher darmerkrankung
DE60234919D1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
WO2006050861A3 (en) Statine derivatives for the treatment of alzheimer's disease
PL1874739T3 (pl) Farmaceutycznie czynne diazepany
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
DE602004031225D1 (de) 3-oxa-8-azaprostaglandinanaloga als mittel zum senken des augeninnendrucks